Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant346 active trials14 approved drugs74 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04221438 | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | terminated | Phase 2 | 3 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 6, 2026 |
| clinicaltrials |
| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2) | terminated | Phase 3 | 70 | SoligenixINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 41 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 1, 2026 | clinicaltrials |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | terminated | N/A | 57 | University Hospital, BordeauxOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | terminated | N/A | 1 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT05110781 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site | terminated | Phase 2 | 1 | University of California, DavisOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)(INTerpath-007) | terminated | Phase 2 / Phase 3 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 20 | May 8, 2026 | clinicaltrials |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | terminated | N/A | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05937672 | Cold Atmospheric Plasma Device Extension Study | terminated | Phase 3 | 60 | Medical University of South CarolinaOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05956795 | Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck | terminated | — | 1 | Johns Hopkins UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03716193 | Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry | terminated | N/A | 3 | West Virginia UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) | terminated | Phase 1 / Phase 2 | 46 | SanofiINDUSTRY | 7 | Feb 4, 2026 | clinicaltrials |
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin | terminated | Phase 1 | 5 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05321784 | At-Home Dermoscopy Artificial Intelligence | terminated | N/A | 1 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT03886181 | Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT) | terminated | N/A | 2 | Alpha Tau Medical LTD.INDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | terminated | Phase 1 / Phase 2 | 31 | NeoImmuneTechINDUSTRY | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment | terminated | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05879458 | Ritlecitinib in CTCL | terminated | Phase 2 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03737721 | The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy(UNSCARRed) | terminated | Phase 2 | 8 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03325101 | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6(ARTISTRY-6) | terminated | Phase 2 | 173 | Mural Oncology, IncINDUSTRY | 8 | Jun 10, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT05436990 | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor | terminated | Phase 2 | 14 | Yonsei UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT00866684 | Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol(PROSKIN) | terminated | Phase 4 | 44 | Charite University, Berlin, GermanyOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | terminated | Phase 1 | 5 | Shattuck Labs, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT04807777 | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma | terminated | Phase 2 | 3 | Columbia UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | terminated | Phase 2 | 3 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04630886 | Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery | terminated | Early Phase 1 | 34 | Riley McLeanOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02097225 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | terminated | Phase 2 | 4 | Providence Health & ServicesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | terminated | — | 54 | Washington University School of MedicineOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 5 | Emory UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides(BDI) | terminated | N/A | 1 | Indiana UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT04846348 | Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis | terminated | Phase 2 | 1 | Joseph ButterfieldOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | terminated | Phase 2 | 29 | Instil BioINDUSTRY | 3 | Apr 16, 2024 | clinicaltrials |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | terminated | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | terminated | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | terminated | Phase 1 / Phase 2 | 1 | Ivan LitvinovOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04337931 | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | terminated | Phase 2 | 45 | Apexigen America, Inc.INDUSTRY | 2 | Feb 13, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials